10x Genomics, Inc. - Common Stock (TXG)

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a strategic collaboration with 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, to establish ImmuneScape™, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ rejection and therapeutic response. Insights generated from this program are intended to support future clinical diagnostic development.

Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.

Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations. Shareholders who have incurred losses on their investment in the Company are encouraged to contact the firm to learn about potentially recovering their losses. For more details on the investigation, visit:

Shares of 10x Genomics, Inc. (NASDAQ: TXG) traded at a new 52-week high today and are currently trading at $59.24. So far today, approximately 246.45k shares have been exchanged, as compared to an average 30-day volume of 913.07k shares.